Using proteomics to advance understanding of Alzheimer’s disease
Using proteomics to advance
understanding of alzheimer’s disease
Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.
You’ll learn how mass spectrometry-based proteomics provides insights into brain changes and assists biomarker discovery in cerebrospinal fluid and plasma, and discover the potential of affinity-based proteomics for reliable biomarker identification. Our expert speaker will delve into intricate networks like proteostasis and the matrisome, highlighting their implications for therapeutic development.
Attend this webinar to:
- Gain insights into the landscape of AD brain changes using unbiased mass spectrometry-based proteomics
- Learn about biomarker discovery in AD cerebrospinal fluid and plasma through multi-platform proteomic analysis
- Understand the potential of affinity-based proteomics, including modified aptamer technology, in identifying reliable biomarkers for AD
- Explore the intricate networks associated with AD pathology and their implications for therapeutic development
Erik Johnson, MD, PhD
Assistant Professor, Department of Neurology
Emory University
Erik Johnson, MD, PhD, is an Assistant Professor in the Department of Neurology and a member of the Goizueta Alzheimer’s Disease Research Center and Center for Neurodegenerative Diseases at Emory University. He is a cognitive neurologist with an active clinical practice who sees patients with Alzheimer’s disease and other cognitive disorders. His research interests focus on using proteomics to understand the biochemical mechanisms that underlie Alzheimer’s disease and to develop molecular fluid biomarkers for these pathological changes. He is actively involved in large consortium research efforts on AD including the Accelerating Medicine Partnership – Alzheimer’s Disease (AMP-AD) consortium and the Dominantly Inherited Alzheimer Disease (DIAN) consortium.
Using proteomics to advance understanding of alzheimer’s disease
A presentation by Erik Johnson, MD, PhD
More webinars
WebinarEvaluation of precision and correlation for the latest proteomic platforms
The field of proteomics is rapidly advancing, enabling precise measurement of thousands of proteins, particularly those in higher abundance. This webcast will explore significant differences in precision within and across the latest large-scale proteomic platforms and their intercorrelations, based on blind duplicate split assays of the leading modified aptamer-based 11K and antibody proximity ligation-based 5K platforms. Each platform exhibits distinct strengths and limitations, requiring careful consideration prior to implementation in individual studies.
WebinarScaling Proteomics: Balancing Performance and Measuring Enough Proteins
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains? To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.
WebinarFrom discovery to clinical insights – the power of integrating proteomics and genomics data
The value of adding high-plex proteomics to existing genomics data and how proteogenomic approaches accelerate drug target discovery and repurposing. Watch this presentation given by Maik Pietzner, PhD, at ESHG 2024.